NRXP

NRx Pharmaceuticals, Inc.

Healthcare
Biotechnology
$59M market cap

Forecast run · Sep 14, 2026Upside rank 507 of 3,136

Model Signal

ForecastQ Daily Probabilities

55.5%

41.3%

33.6%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$3.40

Price target$2.00

Implied move-41.2%

Analysts5

ForecastQ Portfolios

NRXP is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.